J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc.

AGI Introduces Next-Gen, High-Capacity Auger Series At 2023 National Farm Machinery Show

Retrieved on: 
Thursday, February 9, 2023
Agriculture, Natural Resources, Manufacturing, Machinery, Engineering, Serviceability, National Farm Machinery Show, Farmer, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., Element, Isle of Man gas industry, AGI, Noise, Grain, Maintenance, LED, AR, Electric battery, Conveyor system, Rosenort

The AGI Westfield MKX2 auger features an A-frame hydraulic lift system and the AGI Hutchinson-Mayrath HX2 auger features a scissor hydraulic lift system.

Key Points: 
  • The AGI Westfield MKX2 auger features an A-frame hydraulic lift system and the AGI Hutchinson-Mayrath HX2 auger features a scissor hydraulic lift system.
  • AGI will be displaying the Westfield MKX 2 and Hutchinson-Mayrath HX2 augers at next week’s National Farm Machinery Show (Booth 7423),” said Manness.
  • AGI is a provider of solutions for global food infrastructure including seed, fertilizer, grain, feed, and food processing systems.
  • AGI has manufacturing facilities in Canada, the United States, Brazil, India, France, and Italy and distributes its product globally.

$221+ Billion Worldwide Sewage Treatment Facilities Industry to 2031 - Increased Pressure from Governments on Companies and Increasing Investments in the Market Drives Growth

Retrieved on: 
Saturday, January 21, 2023
Benchmark, Sewage, Coronavirus, Pesticide, Hitachi, PAC, Emerson, GE, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., Adsorption, Growth, Buckman (company), Pressure, Wastewater treatment, Organization, Create, Investment, Carbon, California Substance Abuse Treatment Facility and State Prison, Corcoran, Sewage treatment, Marketing

This report provides strategists, marketers and senior management with the critical information they need to assess the global Sewage Treatment Facilities market.

Key Points: 
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global Sewage Treatment Facilities market.
  • This report focuses on Sewage Treatment Facilities market which is experiencing strong growth.
  • The growth in the sewage treatment facilities market is due to the increased pressure from governments on companies, and increasing investments in the market.
  • The countries covered in the sewage treatment facilities market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA.

Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates

Retrieved on: 
Thursday, January 26, 2023
AML, Placenta, Employment, Natural killer cell, ECM, ASX, Osteoarthritis, Safety, Stomach, Trauma, CELU, OA, IND, KOA, Wound healing, TCR, CH, Synovial fluid, Chondrogenesis, Therapy, Cytokine, Umbilical cord, Muscular dystrophy, GBM, Cartilage, Neoplasm, CAR, NK, Patient, Knee, FDA, CD19, Glioblastoma, FSHD, Instituto de Biologia Molecular e Celular, IMU, Workforce, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., Hematological Cancer Research Investment and Education Act, World Health Organization, National academy, Pain, Pharmaceutical industry, Fine chemical, Silk, Phosphorus, Vaccine

FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity,” the “Company”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial-based regenerative therapeutics products, announced today the results of a strategic review of its 2023 key initiatives. This strategic review included the recently announced territory distribution agreement covering more than 100 countries for Celularity’s Halal-Certified products and the exclusive distribution agreement with the Tamer Group in Saudi Arabia. Celularity’s review also included pipeline prioritization and targeted expense reductions to align operating priorities in advance of an anticipated biomaterials production ramp-up this year.

Key Points: 
  • Celularity’s review also included pipeline prioritization and targeted expense reductions to align operating priorities in advance of an anticipated biomaterials production ramp-up this year.
  • Celularity’s advanced biomaterial products include:
    Biovance®, a decellularized, dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy.
  • Celularity continues to believe that genetically modified NK cells will be an important option to improve the current standard of care.
  • However, given the Company’s strategic review, it will deprioritize this study while it continues to optimize its modified and unmodified NK cell platform.

Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia

Retrieved on: 
Wednesday, January 11, 2023
Oncology, Health, Consumer, Infectious Diseases, Stem Cells, Religion, Biotechnology, Gulf Cooperation Council, Degenerative disease, Arabian Peninsula, Umbilical cord, Public health, Tamer, Organisation of Islamic Cooperation, Trauma, Partner (business rank), CELU, Therapy, CH, Placenta, Instituto de Biologia Molecular e Celular, Research, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., Wound healing, African Union, Organization, United Arab Emirates, Pharmaceutical industry, Medical device, Cryptocurrency, Silk

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading Group”), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group (“Tamer”).

Key Points: 
  • Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading Group”), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group (“Tamer”).
  • The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity’s branded regenerative biomaterial products in Saudi Arabia.
  • “We are looking forward to partnering with Celularity and CH Group on this exciting opportunity across Saudi Arabia and providing unprecedented access to these cutting-edge therapeutics to all members of the community,” stated Dr. Yasser Khattab, Tamer Group Healthcare CEO.
  • “Saudi Arabia is a prime market for Celularity’s commercial regenerative biomaterial products,” said CEO of CH Trading Group, Sayed Zayan.

Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East

Retrieved on: 
Wednesday, January 11, 2023
Oncology, Health, Infectious Diseases, Logistics, Supply Chain Management, Transport, Pharmaceutical, Biotechnology, Gulf Cooperation Council, Degenerative disease, Umbilical cord, Organisation of Islamic Cooperation, Trauma, Product distribution, Partnership, CELU, CH, Placenta, Instituto de Biologia Molecular e Celular, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., Wound healing, Islamic marketing, African Union, Organization, United Arab Emirates, Regenerative medicine, Pharmaceutical industry, Silk

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading Group”), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement.

Key Points: 
  • Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading Group”), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement.
  • CH Trading Group will act as the exclusive territories distributor of Celularity’s previously announced Halal-Certified products within more than 100 countries.
  • The Product Distribution Agreement for Celularity’s Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.
  • “Based on market demand for Celularity’s commercial biomaterial products, we believe there is a billion-dollar commercial opportunity across the Middle East North Africa Islamic markets,” said Sayed Zayan, CEO of CH Trading Group.

Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East

Retrieved on: 
Wednesday, January 11, 2023
Gulf Cooperation Council, Degenerative disease, Umbilical cord, Organisation of Islamic Cooperation, Trauma, Health, Product distribution, Partnership, CELU, CH, Placenta, Instituto de Biologia Molecular e Celular, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., Wound healing, Islamic marketing, African Union, Organization, United Arab Emirates, Regenerative medicine, Islam, Silk, Pharmaceutical industry

FLORHAM PARK, N.J., RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement. CH Trading Group will act as the exclusive territories distributor of Celularity's previously announced Halal-Certified products within more than 100 countries. The Product Distribution Agreement for Celularity's Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.   

Key Points: 
  • Relationship opens access to Celularity's Halal-Certified regenerative biomaterial, health and wellness products across the Middle East and the broader Islamic world
    FLORHAM PARK, N.J., RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement.
  • CH Trading Group will act as the exclusive territories distributor of Celularity's previously announced Halal-Certified products within more than 100 countries.
  • The Product Distribution Agreement for Celularity's Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.
  • "Based on market demand for Celularity's commercial biomaterial products, we believe there is a billion-dollar commercial opportunity across the Middle East North Africa Islamic markets," said Sayed Zayan,  CEO of CH Trading Group.

Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East

Retrieved on: 
Wednesday, January 11, 2023
Gulf Cooperation Council, Degenerative disease, Umbilical cord, Organisation of Islamic Cooperation, Trauma, Health, Product distribution, Partnership, CELU, CH, Placenta, Instituto de Biologia Molecular e Celular, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., Wound healing, Islamic marketing, African Union, Organization, United Arab Emirates, Regenerative medicine, Islam, Silk, Pharmaceutical industry

FLORHAM PARK, N.J., RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement. CH Trading Group will act as the exclusive territories distributor of Celularity's previously announced Halal-Certified products within more than 100 countries. The Product Distribution Agreement for Celularity's Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.   

Key Points: 
  • Relationship opens access to Celularity's Halal-Certified regenerative biomaterial, health and wellness products across the Middle East and the broader Islamic world
    FLORHAM PARK, N.J., RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement.
  • CH Trading Group will act as the exclusive territories distributor of Celularity's previously announced Halal-Certified products within more than 100 countries.
  • The Product Distribution Agreement for Celularity's Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.
  • "Based on market demand for Celularity's commercial biomaterial products, we believe there is a billion-dollar commercial opportunity across the Middle East North Africa Islamic markets," said Sayed Zayan,  CEO of CH Trading Group.

Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia

Retrieved on: 
Wednesday, January 11, 2023
Gulf Cooperation Council, Degenerative disease, LifeBank, Umbilical cord, Vision 2030, Public health, Organisation of Islamic Cooperation, Trauma, Partner (business rank), Health, CELU, Therapy, CH, Placenta, Research, Wound healing, Islamic marketing, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., African Union, Pakistan and the Organisation of Islamic Cooperation, Organization, United Arab Emirates, Silk, Weapon, Medical device, Kingdom, Instituto de Biologia Molecular e Celular

FLORHAM PARK, N.J, RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group ("Tamer"). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity's branded regenerative biomaterial products in Saudi Arabia.

Key Points: 
  • Tamer Group will be the exclusive distributor of the Celularity branded biomaterial products in Saudi Arabia, opening access to Celularity's Halal-Certified regenerative biomaterial, health and wellness products
    FLORHAM PARK, N.J, RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group ("Tamer").
  • The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity's branded regenerative biomaterial products in Saudi Arabia.
  • "Saudi Arabia is a prime market for Celularity's commercial regenerative biomaterial products," said CEO of CH Trading Group, Sayed Zayan.
  • "We are excited to partner with Tamer Group and to be a part of fulfilling their commitment to the development of the Kingdom's healthcare sector."

Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia

Retrieved on: 
Wednesday, January 11, 2023
Gulf Cooperation Council, Degenerative disease, LifeBank, Umbilical cord, Vision 2030, Public health, Organisation of Islamic Cooperation, Trauma, Partner (business rank), Health, CELU, Therapy, CH, Placenta, Research, Wound healing, Islamic marketing, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., African Union, Pakistan and the Organisation of Islamic Cooperation, Organization, United Arab Emirates, Silk, Medical device, Kingdom, Instituto de Biologia Molecular e Celular

FLORHAM PARK, N.J, RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia , Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group ("Tamer"). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity's branded regenerative biomaterial products in Saudi Arabia.

Key Points: 
  • Tamer Group will be the exclusive distributor of the Celularity branded biomaterial products in Saudi Arabia, opening access to Celularity's Halal-Certified regenerative biomaterial, health and wellness products
    FLORHAM PARK, N.J, RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia , Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group ("Tamer").
  • The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity's branded regenerative biomaterial products in Saudi Arabia.
  • "Saudi Arabia is a prime market for Celularity's commercial regenerative biomaterial products," said CEO of CH Trading Group, Sayed Zayan.
  • "We are excited to partner with Tamer Group and to be a part of fulfilling their commitment to the development of the Kingdom's healthcare sector."

Bee Vectoring Technologies Announces Commercial Agreement with BioSafe Systems to Sell CR-7 Products into Foliar and Soil Drench Markets

Retrieved on: 
Tuesday, January 10, 2023
Soil, MOU, Clonostachys, CVE, China Biologic Products, CSE, Plant, Agriculture, Horticulture, Health, Partnership, Marketing, History, Growth, Food, Farmer, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., BVT, AG, Pharmaceutical industry, Citrus, EU

Mississauga, Ontario and Sacramento, California--(Newsfile Corp. - January 10, 2023) - Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF) (CVE: BEE) (the "Company" or "BVT") and BioSafe Systems jointly announced a signed commercial agreement.

Key Points: 
  • Mississauga, Ontario and Sacramento, California--(Newsfile Corp. - January 10, 2023) - Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF) (CVE: BEE) (the "Company" or "BVT") and BioSafe Systems jointly announced a signed commercial agreement.
  • "It follows our January 2022 announcement of the MOU with BioSafe , and now has successfully moved into a commercial agreement after completing discussions and evaluations."
  • "Our CR-7 franchise extends our Company's reach beyond bee vectoring distribution and into the much larger market for foliar and soil-applied crop protection products.
  • Soil drench applications are used to manage soil pathogens that affect the roots of plants and can provide systemic protection as well as crop health and enhancements.